Drug Discovery– tag –
-
Frontier of Therapy Series: “Training” Immunity to Fight Cancer — CAR-T at a Glance (From Beginner to Expert) | B2: Toxicity Management, Site Operations & Long-Term Safety (Including Regulatory Logic) [Expert]
Prefer the beginner overview first?→ A0: What is CAR-T therapy? The big picture + index→ A2: CAR-T side effects without panic (what happens, what to monitor) “CAR-T Toxicity Management: Timeline × Actions × Follow-Up”Left: Day 0–14 (CRS/... -
Frontier of Therapy Series: “Training” Immunity to Fight Cancer — CAR-T at a Glance (From Beginner to Expert) | A2: CAR-T Side Effects Without Panic — What Can Happen & What to Monitor [Beginner]
New here? Start with the basics and where CAR-T is used today.→ A0: What Is CAR-T Therapy? The Big Picture + Series Index→ A1: Where CAR-T Is Used Today — Blood Cancers First Want the deep dive (B2)? We will cover severity grading concep... -
Frontier of Therapy Series: “Training” Immunity to Fight Cancer — CAR-T at a Glance (From Beginner to Expert) | B1: FDA-Approved CAR-T Landscape (Products, Targets, Companies, Label Logic) [Expert]
Prefer the beginner overview first?→ A0: What is CAR-T therapy? The big picture + index→ A1: Where CAR-T is used today (blood cancers first) Executive summary FDA-approved oncology CAR-T products cluster around two core targets: CD19 (B-... -
Frontier of Therapy Series: “Training” Immunity to Fight Cancer — CAR-T at a Glance (From Beginner to Expert) | A1: Where CAR-T Is Used Today — The Big Picture (Blood Cancers First) [Beginner]
New here? If you haven’t read the introduction, it will make this post much easier to follow.→ A0: What Is CAR-T Therapy? The Big Picture + Series Index Want the deep dive? The expert post (B1) will organize FDA-approved CAR-T products b... -
Frontier of Therapy Series: “Training” Immunity to Fight Cancer — CAR-T at a Glance (From Beginner to Expert) | A0: What Is CAR-T Therapy? The Big Picture, in Plain Language [Beginner]
How to use this series (two-layer linkage: Beginner → Expert) This series explains CAR-T therapy in a stepwise way so that readers who are new to the term can first grasp the big picture (Layer A), and then move to the expert layer (Laye... -
Oncology Drug Approval News Flash FDA approves teclistamab (Tecvayli) plus daratumumab hyaluronidase-fihj for relapsed/refractory multiple myeloma (and converts Tecvayli monotherapy from accelerated to traditional approval)
On March 5, 2026, the U.S. FDA approved teclistamab (Tecvayli), a BCMA×CD3 bispecific antibody, in combination with daratumumab hyaluronidase-fihj for adults with relapsed or refractory multiple myeloma (RRMM) who have received at least ... -
Oncology Drug Approval News Flash: Encorafenib plus cetuximab and fluorouracil-based chemotherapy receives traditional FDA approval for BRAF V600E–mutated metastatic colorectal cancer
FDA approval summary On February 24, 2026, the U.S. Food and Drug Administration (FDA) granted traditional approval to encorafenib (Braftovi, Array BioPharma Inc., a subsidiary of Pfizer Inc.) in combination with cetuximab and fluorourac... -
Oncology Drug Approval News Flash: Optune Pax, a low electric field tumor treating fields device, approved with gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer
FDA approval summary On February 11, 2026, the U.S. Food and Drug Administration (FDA) approved a low electric field generator device, Optune Pax (Novocure), in combination with gemcitabine and nab-paclitaxel for the treatment of adult p... -
Oncology Drug Approval News Flash: Pembrolizumab plus paclitaxel with or without bevacizumab approved for platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma
FDA approval summary On February 10, 2026, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda, Merck) and pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex, Merck) in combination with paclitaxel, with... -
From Beginner to Expert: AI in Drug Discovery – A Definitive Guide from Lab to Market (Extra Chapter, Snapshot as of November 22, 2025) focuses only on the latest AI-driven case studies and summarizes how far AI has actually progressed in real drug discovery and development.
1. Where Does AI in Drug Discovery Stand in 2025? Between 2024 and 2025, AI in drug discovery has quietly moved from the “proof-of-concept” phase into a stage where AI-designed molecules are showing signals in human trials. At the same t... -
From Beginner to Expert: AI in Drug Discovery – A Definitive Guide from Lab to Market (Part 7: “Putting It All Together”) summarizes a cross-modality roadmap for AI in drug discovery and development, clarifies what AI can and cannot realistically do, and outlines strategic considerations from lab bench to market access.
1. Recap: A Cross-Modality “AI in Drug Discovery” Map In Parts 1–6, we walked through: Small molecules × AI Antibodies, bispecifics, and ADCs × AI Nucleic acid and RNA therapeutics × AI Cell and gene therapies × AI Each time, we looked a... -
From Beginner to Expert: AI in Drug Discovery – A Definitive Guide from Lab to Market (Part 6: “Cell & Gene Therapy × AI”) maps how AI is used from CAR-T/TCR and vector design to manufacturing and quality control, and clarifies both its potential and its current limitations in these complex modalities.
1. Why “Cell & Gene Therapy × AI” Is Both Difficult and Important In Part 6, we focus on cell therapies (e.g., CAR-T, TCR-T) and gene therapies (e.g., AAV or lentiviral vectors). Compared with small molecules, antibodies, or RNA ther... -
Aging and Cancer Extra Edition – Part 2 The Global Frontline of Longevity Biotech: What Are Unity, BioAge, Cambrian, and Altos Trying to Achieve?
Introduction: Aging Is Becoming an Industry In Extra Edition Part 1, we introduced the concept of “anti-aging drugs” by looking at major mechanisms such as mTOR, metformin, senolytics, NAD⁺, and cellular reprogramming. We focused on how ... -
How Far Can We Trust Genome AI? — Reading AlphaGenome (Nature) with an Implementation Mindset (Expert Edition)
In the beginner edition, we focused on why the “other 98%” of DNA (non-coding regions) is hard to interpret and why genome AI should be framed as hypothesis generation and prioritization, not as an “answer machine.” This Expert Edition g... -
Aging and Cancer Extra Edition – Part 1 What Are “Anti-Aging Drugs”? An Introductory Guide from Metformin and mTOR to Senolytics and “Rejuvenation”
Introduction: Why Are “Anti-Aging Drugs” a Hot Topic Now? When you hear “anti-aging drugs” or “rejuvenation pills,” you might imagine dubious supplements or flashy beauty ads. However, what many academic groups, pharmaceutical companies,... -
What Does the “Other 98%” of DNA Do? — A Beginner-Friendly Guide to Genome AI (What DeepMind’s AlphaGenome Suggests)
When people hear “genome analysis,” they often imagine a simple story: read DNA, find a mutation, and explain a disease. In reality, the deeper we read, the more often we hit a frustrating wall: we can detect many variants, but we can’t ... -
From Beginner to Expert: AI in Drug Discovery – A Definitive Guide from Lab to Market (Part 5: “Nucleic Acid & RNA Therapeutics × AI”) summarizes how AI is used for sequence design, target selection, delivery optimization, and safety assessment for RNA and nucleic-acid medicines.
1. Why “Nucleic Acid & RNA Therapeutics × AI” Matters mRNA vaccines, siRNA, antisense oligonucleotides (ASOs), saRNA, and CRISPR guide RNAs have rapidly moved from concept to clinical reality. In these modalities, the design space is... -
The more important question than “present or absent”: how microbial elements may tune immunity in brain tumors
Brain tumors sit at the crossroads of immunology and microbiology, but they are also a uniquely challenging environment to study. The blood–brain barrier (BBB) and the inherently low-biomass nature of brain tissue make it difficult to me... -
From Beginner to Expert: AI in Drug Discovery – A Definitive Guide from Lab to Market (Part 4: “Antibodies & Biologics × AI”) explores how AI is applied to sequence design, affinity maturation, and developability prediction, and how this differs from small-molecule use cases.
1. Why “Antibodies & Biologics × AI” Is Different from Small Molecules In Part 3, we focused on small-molecule projects. In Part 4, we turn to antibodies and biologics (including antibodies, bispecifics, antibody–drug conjugates, and... -
Oncology Drug Approval News Flash: Daratumumab and hyaluronidase-fihj plus bortezomib, lenalidomide, and dexamethasone approved for newly diagnosed multiple myeloma in transplant-ineligible adults
FDA approval summary On January 27, 2026, the U.S. Food and Drug Administration (FDA) approved daratumumab and hyaluronidase-fihj (Darzalex Faspro, Janssen Biotech, Inc.) in combination with bortezomib, lenalidomide, and dexamethasone (V...
